Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BETOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BETOPTIC.
BETAPACE vs BETOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker